BACKGROUND Liver cancer is the fourth leading cause of cancer-related death globally which is estimated to reach more than 1 million deaths a year by 2030. Among liver cancer types, hepatocellular carcinoma (HCC) accounts for approximately 90% of the cases and is known to have a tumour promoting inflammation regardless of its underlying aetiology. However, current promising treatment approaches, such as immunotherapy, are partially effective for most of the patients due to the immunosuppressive nature of the tumour microenvironment (TME). Therefore, there is an urgent need to fully understand TME in HCC and discover new immune markers to eliminate resistance to immunotherapy. METHODS We analyse three microarray datasets, using unsu...
Background: Hepatocellular carcinoma (HCC) is a highly heterogeneous disease with the high rates of ...
Hepatocellular carcinoma is a common malignant tumor with poor prognosis, poor treatment effect, and...
Background: Hepatocellular carcinoma (HCC) is the most common primary liver malignancy with high mor...
BACKGROUND Liver cancer is the fourth leading cause of cancer-related death globally which is est...
Abstract Background Hepatocellular carcinoma (HCC) is often caused by chronic liver infection or inf...
BACKGROUND & AIMS: Agents that induce an immune response against tumors by altering T-cell regulatio...
Background: The antitumor immune response may play a major role in the clinical outcome of hepatocel...
Background. Hepatocellular carcinoma (HCC) is the leading liver cancer with special immune microenvi...
BackgroundM2-like tumor-associated macrophages (M2-like TAMs) have important roles in the progressio...
Background: Tumor growth depends on tumor cells and the tumor microenvironment, which are regulated ...
Background: The prognosis of patients with hepatocellular carcinoma (HCC) is negatively affected by ...
BackgroundM2-like tumor-associated macrophages (M2-like TAMs) have important roles in the progressio...
Background: Hepatocellular carcinoma (HCC) is a malignancy with a poor prognosis. This study aimed t...
Background: Immune checkpoint inhibitor (ICI) therapy has been proved to be a promising therapy to m...
BackgroundM2-like tumor-associated macrophages (M2-like TAMs) have important roles in the progressio...
Background: Hepatocellular carcinoma (HCC) is a highly heterogeneous disease with the high rates of ...
Hepatocellular carcinoma is a common malignant tumor with poor prognosis, poor treatment effect, and...
Background: Hepatocellular carcinoma (HCC) is the most common primary liver malignancy with high mor...
BACKGROUND Liver cancer is the fourth leading cause of cancer-related death globally which is est...
Abstract Background Hepatocellular carcinoma (HCC) is often caused by chronic liver infection or inf...
BACKGROUND & AIMS: Agents that induce an immune response against tumors by altering T-cell regulatio...
Background: The antitumor immune response may play a major role in the clinical outcome of hepatocel...
Background. Hepatocellular carcinoma (HCC) is the leading liver cancer with special immune microenvi...
BackgroundM2-like tumor-associated macrophages (M2-like TAMs) have important roles in the progressio...
Background: Tumor growth depends on tumor cells and the tumor microenvironment, which are regulated ...
Background: The prognosis of patients with hepatocellular carcinoma (HCC) is negatively affected by ...
BackgroundM2-like tumor-associated macrophages (M2-like TAMs) have important roles in the progressio...
Background: Hepatocellular carcinoma (HCC) is a malignancy with a poor prognosis. This study aimed t...
Background: Immune checkpoint inhibitor (ICI) therapy has been proved to be a promising therapy to m...
BackgroundM2-like tumor-associated macrophages (M2-like TAMs) have important roles in the progressio...
Background: Hepatocellular carcinoma (HCC) is a highly heterogeneous disease with the high rates of ...
Hepatocellular carcinoma is a common malignant tumor with poor prognosis, poor treatment effect, and...
Background: Hepatocellular carcinoma (HCC) is the most common primary liver malignancy with high mor...